

Novel food: bovine milk beta-lactoglobulin

Published by AGRINFO on 11 Jan 2023

European Commission authorises bovine milk beta-lactoglobulin as a novel food

Commission Implementing Regulation (EU) [2022/2534](#) of 21 December 2022 authorising the placing on the market of bovine milk beta-lactoglobulin (β -lactoglobulin) as a novel food and amending Implementing Regulation (EU) 2017/2470

Update

The European Commission has authorised bovine milk beta-lactoglobulin (β -lactoglobulin) as a novel food.

Impacted products

exercise drinks, whey powder, milk-based drinks, foods for special medical purposes

What is changing?

The EU has authorised that bovine milk β -lactoglobulin may be placed on the EU market as a novel food. The food can be used in soft drinks marketed in relation to physical exercise, whey powder, milk-based drinks and similar products, and in foods for special medical purposes. Details on the permitted use are set out in the Annex to the Regulation.

Only the company that applied for the authorisation, Arla Foods Ingredients Group P/S, is authorised to place the novel food on the EU market for a period of 5 years, unless another company obtains a novel food authorisation for β -lactoglobulin (without reference to scientific data protected by Arla Foods Ingredients Group) or with the agreement of Arla Foods Ingredients Group.

Timeline

The 5-year period of exclusive rights of Arla Foods Ingredients Group to put this novel food on the market ends on 11 January 2028.

Background

This Regulation updates the Annex to Implementing Regulation (EU) [2017/2470](#) which lists authorised novel foods (see the [Union list of novel foods](#)).

Resources

Regulation (EU) [2015/2283](#) on novel foods

Sources

Commission Implementing Regulation (EU) [2022/2534](#)

Commission Implementing Regulation (EU) [2017/2470](#) (Union list of novel foods)

Regulation (EU) [2015/2283](#) on novel foods

Disclaimer: *Under no circumstances shall COLEAD be liable for any loss, damage, liability or expense incurred or suffered that is claimed to have resulted from the use of information available on this website or any link to external sites. The use of the website is at the user's sole risk and responsibility. This information platform was created and maintained with the financial support of the European Union. Its contents do not, however, reflect the views of the European Union.*